Menée à l'aide de données portant sur 12 609 personnes âgées d'au moins 70 ans et incluses dans un essai randomisé (durée médiane de suivi : 4,7 ans), cette étude analyse l'efficacité chimiopréventive de l'utilisation d'aspirine chez les personnes présentant un risque plus élevé de cancer colorectal

Aspirin and the risk of colorectal cancer according to genetic susceptibility among older individuals

Bakshi, Andrew ; Cao, Yin ; Orchard, Suzanne G. ; Carr, Prudence R. ; Joshi, Amit D. ; Manning, Alisa K. ; Buchanan, Daniel D. ; Umar, Asad ; Winship, Ingrid M. ; Gibbs, Peter ; Zalcberg, John R. ; Macrae, Finlay ; McNeil, John J. ; Lacaze, Paul ; Chan, Andrew T.

Although aspirin has been considered a promising agent for prevention of colorectal cancer (CRC), recent data suggest a lack of benefit among older individuals. Whether some individuals with higher risk of CRC may benefit from aspirin remains unknown. We used a 95-variant CRC polygenic risk score (PRS) to explore the association between genetic susceptibility to CRC and aspirin use in a prospective study of 12,609 individuals of European descent aged {greater than or equal to} 70 years, [...]

Menée en Angleterre auprès de 108 138 femmes âgées de 24 à 29 ans, cette étude analyse l'effet, sur les taux de détection de lésions cervicales intraépithéliales de haut grade, du vaccin anti-papillomavirus humain bivalent proposé en rattrapage aux adolescentes entre 14 et 17 ans

The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot

Rebolj, Matejka ; Pesola, Francesca ; Mathews, Christopher ; Mesher, David ; Soldan, Kate ; Kitchener, Henry

Background: In England, bivalent vaccination (Cervarix) against high-risk human papillomavirus (HR-HPV) genotypes 16/18 was offered in a population-based catch-up campaign in 2008–2010 to girls aged 14–17 years. These women are now entering the national cervical screening programme. We determined the impact of catch-up bivalent vaccination on their screening outcomes. Methods: We studied the overall and genotype-specific screening outcomes in 108,138 women aged 24–25 (offered vaccination) and [...]